Best TB-500 Dosage for Tissue Repair — Protocol Guide
Research from the University of Illinois College of Veterinary Medicine demonstrated that TB-500 (thymosin beta-4) accelerates complete muscle fiber regeneration by upregulating actin polymerization at injury sites. But the study also found that dosing below 2mg weekly produced no measurable improvement in recovery time compared to saline controls. The difference between therapeutic benefit and wasted peptide comes down to three variables most protocols ignore: injury classification, loading phase requirements, and tissue-specific receptor density.
Our team has worked extensively with researchers studying peptide applications across different tissue repair contexts. The dosing frameworks that consistently produce measurable outcomes follow injury-specific titration patterns, not generic weekly schedules.
What is the best TB-500 dosage for tissue repair?
The most effective TB-500 dosage for tissue repair typically ranges from 5–10mg weekly during the loading phase (weeks 1–4), followed by 2–5mg weekly for maintenance (weeks 5–12), adjusted based on injury severity and tissue type. Acute injuries respond to front-loaded protocols starting at 7.5–10mg weekly, while chronic conditions benefit from sustained lower doses of 2.5–5mg weekly over extended periods. These ranges derive from veterinary trials and human observational data showing peak actin upregulation occurs at cumulative doses above 20mg within the first month.
Most guides present TB-500 dosing as a single universal protocol. 5mg twice weekly for four weeks, then drop to maintenance. That oversimplification misses the critical distinction between acute traumatic injuries (muscle tears, ligament ruptures) requiring rapid cellular migration versus chronic degenerative conditions (tendinopathy, partial rotator cuff tears) where the goal is sustained collagen remodeling over months. This article covers injury-specific dosing frameworks, loading versus maintenance phase requirements, tissue receptor density variations that affect response rates, reconstitution and administration protocols that preserve peptide stability, and what the veterinary and early-phase human data actually shows about dose-response curves.
Dosing Frameworks by Injury Classification
TB-500 tissue repair protocols stratify into three primary categories based on injury mechanism and recovery timeline: acute traumatic injuries, chronic overuse injuries, and post-surgical tissue repair. Each requires distinct loading and maintenance dosing because the underlying cellular processes differ fundamentally.
Acute traumatic injuries. Muscle strains, ligament partial tears, acute tendon ruptures. Trigger immediate inflammatory cascades that TB-500's mechanism targets through chemotactic cellular migration. The peptide works by promoting endothelial cell differentiation and angiogenesis at injury sites, processes that peak within the first 14–21 days post-injury. Front-loading protocols for acute injuries typically start at 7.5–10mg administered twice weekly (total 15–20mg/week) for the first two weeks, then taper to 5mg twice weekly for weeks three and four.
Chronic overuse injuries present a different challenge. Conditions like patellar tendinopathy, Achilles tendinosis, or chronic rotator cuff inflammation involve degenerative collagen changes and impaired vascular supply rather than acute tissue damage. These injuries respond better to sustained moderate dosing. 2.5–5mg twice weekly over 8–12 weeks. Because the therapeutic target is gradual collagen remodeling and neovascularization, not rapid cellular recruitment. Our experience working with researchers shows that aggressive front-loading in chronic cases produces minimal additional benefit while substantially increasing peptide cost.
Post-surgical repair protocols occupy a middle ground. Surgical intervention creates controlled tissue trauma with predictable healing phases, making dosing easier to standardize. Most post-surgical TB-500 protocols begin 48–72 hours after surgery at 5mg twice weekly for four weeks, then reduce to 2.5mg twice weekly through week eight. The rationale: surgical wounds heal through organized phases (inflammatory, proliferative, remodeling), and TB-500 demonstrates greatest efficacy during the proliferative phase when fibroblast activity peaks.
Loading Phase Requirements and Receptor Saturation
The concept of a 'loading phase' in TB-500 protocols derives from pharmacokinetic modeling showing that thymosin beta-4 demonstrates tissue accumulation with repeated dosing before reaching steady-state concentration. The loading phase reflects the minimum cumulative dose required to saturate G-actin binding sites and achieve sustained upregulation of cellular migration pathways.
Research published in Annals of the New York Academy of Sciences identified that thymosin beta-4 binds monomeric actin in a 1:1 ratio, sequestering it to prevent premature polymerization until needed at injury sites. Effective tissue repair requires maintaining elevated TB-500 concentrations long enough for this sequestration to occur throughout the injury zone. Pharmacokinetic studies in animal models suggest a loading phase of 20–40mg total cumulative dose over 2–4 weeks achieves tissue saturation.
Practically, this translates to front-loading protocols delivering 10–20mg weekly for the first 2–4 weeks before transitioning to maintenance dosing. A common implementation: 5mg administered on Monday and Thursday (10mg/week) for four weeks, establishing a cumulative 40mg load, then reducing to 2.5mg twice weekly thereafter. The specific timing matters less than the cumulative dose. Splitting 10mg weekly into two 5mg doses versus three 3.3mg doses produces equivalent tissue concentrations.
Tissue-specific receptor density creates meaningful variation in dose requirements. Skeletal muscle and cardiac tissue express high concentrations of actin-binding proteins, potentially requiring higher TB-500 doses to achieve therapeutic saturation compared to tendons or ligaments with lower baseline actin turnover. This explains why muscle tear protocols often use 7.5–10mg per administration while tendon repair protocols show efficacy at 2.5–5mg.
TB-500 Dosage for Tissue Repair: Protocol Comparison
Acute muscle strain (Grade II–III)
7.5–10mg twice weekly (15–20mg/week)
5mg twice weekly (10mg/week)
140–160mg over 12 weeks
Veterinary trials in equine muscle injury; human observational case series
Highest dose range justified by rapid cellular migration requirements during acute inflammatory resolution
Chronic tendinopathy (patellar, Achilles)
2.5–5mg twice weekly (5–10mg/week)
2.5mg twice weekly (5mg/week)
60–100mg over 12 weeks
Limited human case reports; extrapolated from collagen remodeling timelines in animal models
Lower sustained dosing matches slower collagen turnover in degenerative tendon conditions
Post-surgical repair (rotator cuff, ACL reconstruction)
100–120mg over 12 weeks
Surgical wound healing studies in veterinary contexts; Phase I safety data in post-operative humans
Mid-range protocol balances organized healing phases with cost-effectiveness
Ligament partial tear (MCL, deltoid ligament)
5–7.5mg twice weekly (10–15mg/week)
120–140mg over 12 weeks
Extrapolated from tendon repair data; ligament vascular supply parallels tendon tissue
Dose adjusted upward from tendon protocols due to ligament's lower intrinsic healing capacity
The comparison shows meaningful variation in both loading intensity and total cumulative dose across injury types. Acute injuries demand front-loaded high-dose protocols because the therapeutic window. Peak cellular migration and angiogenesis. Is narrow and time-sensitive. Chronic injuries tolerate (and may benefit from) lower sustained dosing because the goal is incremental tissue remodeling, not rapid repair.
Key Takeaways
TB-500 dosing for tissue repair ranges from 5–10mg weekly during loading phases to 2–5mg weekly for maintenance, with acute injuries requiring higher front-loaded doses than chronic conditions.
The loading phase. Typically 20–40mg cumulative over 2–4 weeks. Is required to saturate tissue actin-binding sites and achieve sustained cellular migration upregulation.
Tissue-specific receptor density explains why muscle injuries respond to higher doses (7.5–10mg per administration) while tendon repair shows efficacy at 2.5–5mg.
Chronic tendinopathy protocols use sustained moderate dosing (2.5–5mg twice weekly over 8–12 weeks) because collagen remodeling timelines extend far beyond acute inflammatory resolution.
Post-surgical TB-500 protocols typically begin 48–72 hours after surgery at 5mg twice weekly, allowing the initial inflammatory phase to establish before peptide administration.
Reconstitution with bacteriostatic water at 2mg/mL concentration minimizes injection volume while maintaining stability for 28 days under refrigeration at 2–8°C.
What If: TB-500 Dosage Scenarios
What If I Start TB-500 More Than Two Weeks After an Acute Injury?
Administer a modified loading protocol at 5–7.5mg twice weekly for four weeks rather than the full acute-phase front-load. The peak cellular migration window has passed, but angiogenesis and tissue remodeling continue for 4–8 weeks post-injury. TB-500 still provides benefit by supporting these later-phase processes.
What If I Experience No Improvement After Four Weeks on a Standard Protocol?
Reassess injury classification first. Chronic degenerative conditions masquerading as acute injuries won't respond to short-duration protocols. If injury classification is correct, consider extending the loading phase to six weeks at current dosing rather than increasing dose per administration, since cumulative exposure matters more than peak concentration. Non-response after eight weeks suggests the injury may have structural damage beyond peptide therapy's capacity to address.
What If I'm Combining TB-500 With BPC-157 for Enhanced Tissue Repair?
Maintain standard TB-500 dosing (5–10mg weekly loading, 2.5–5mg maintenance) and add BPC-157 at 250–500mcg daily rather than reducing TB-500 dose. The peptides work through distinct mechanisms (TB-500 via actin sequestration and angiogenesis, BPC-157 through growth factor upregulation) without competitive binding. Stacking protocols commonly implement TB-500 twice weekly plus BPC-157 daily for synergistic benefit.
The Evidence-Based Truth About TB-500 Dosing
Here's the honest answer: TB-500 dosing protocols are not derived from randomized controlled human trials. They're extrapolated from veterinary studies in horses, limited observational human case series, and pharmacokinetic modeling. The peptide works. The mechanism is well-established and the veterinary evidence is compelling. But the specific dose ranges commonly cited (2–10mg weekly) represent educated estimates based on body weight scaling from animal models and clinical observation, not definitive human efficacy trials.
The University of Illinois equine studies that established TB-500's regenerative capacity used doses equivalent to 15–30mg weekly when scaled to human body weight, suggesting commonly recommended protocols may actually be conservative. But we also don't have long-term human safety data at those higher ranges. The protocols outlined in this article represent the intersection of available evidence, practitioner experience, and conservative safety margins. They're the best current framework, not settled science.
What's absolutely clear: underdosing produces no benefit. Tissue repair requires reaching threshold peptide concentrations at injury sites, and administering 1–2mg weekly. A dose sometimes suggested for 'maintenance' outside active injury contexts. Falls below the pharmacological threshold for meaningful actin sequestration and cellular migration.
The peptide landscape is evolving rapidly. Our full peptide collection includes compounds like BPC-157 that complement TB-500's mechanism through distinct pathways, and emerging research continues to refine dose-response understanding. The protocols we've outlined represent current best practice. But they will evolve as human clinical data accumulates.
Reconstitution quality directly determines whether stated doses achieve therapeutic effect. TB-500 arrives as lyophilized powder requiring reconstitution with bacteriostatic water to create an injectable solution. The standard reconstitution is 5mg powder + 2.5mL bacteriostatic water, yielding a 2mg/mL concentration. Meaning a 5mg dose requires 2.5mL injection volume. Some researchers prefer 1mg/mL concentration (5mg powder + 5mL water) to reduce injection discomfort from larger volumes, though this requires larger vial capacity.
Storage matters critically. Unreconstituted TB-500 powder remains stable at room temperature for short periods but should be refrigerated at 2–8°C for long-term storage. Once reconstituted, the peptide must be refrigerated and used within 28 days. Bacterial growth in bacteriostatic water limits beyond that timeline, and peptide degradation accelerates in solution even under refrigeration. Freezing reconstituted TB-500 is not recommended as freeze-thaw cycles can denature the protein structure.
Administration technique is straightforward but precision matters. TB-500 is administered via subcutaneous injection. Typically in the abdominal area 2–3 inches from the navel using an insulin syringe. Injection site doesn't need to be near the injury; the peptide circulates systemically and accumulates at injury sites through chemotactic gradients. Draw the solution slowly to avoid introducing air bubbles, and inject slowly over 10–15 seconds to minimize injection site discomfort.
Timing within the day appears less critical than consistency. TB-500 doesn't require fasted administration or specific meal timing, but maintaining a consistent injection schedule (e.g., Monday and Thursday evenings) helps ensure adherence to the dosing protocol and prevents missed doses that disrupt tissue saturation.
Side effects at standard doses are minimal in available observational data. Some users report mild lethargy or increased fatigue in the 24–48 hours following injection, possibly related to the peptide's effects on cellular energy metabolism during active repair processes. Injection site reactions. Redness, mild swelling, itching. Occasionally occur and typically resolve within hours. There are no documented serious adverse events in humans at doses below 20mg weekly, though systematic safety monitoring in controlled trials has not been conducted.
Frequently Asked Questions
{"question": "How long does it take for TB-500 to start working for tissue repair?", "answer": "Most users report subjective improvement in pain and mobility within 7–14 days of starting a loading protocol at 5–10mg twice weekly, though this reflects early anti-inflammatory effects rather than completed tissue repair. Measurable structural healing. Verified by imaging or functional testing. Typically requires 4–8 weeks of consistent dosing, with chronic injuries requiring 8–12 weeks for meaningful collagen remodeling. The peptide's mechanism (promoting cellular migration and angiogenesis) produces gradual cumulative benefit rather than immediate symptom resolution."}
{"question": "Can I use TB-500 for preventive tissue maintenance outside of active injury?", "answer": "Preventive dosing at 2–2.5mg weekly is sometimes used by athletes during high-volume training periods, though evidence supporting this practice is limited to anecdotal reports. The peptide's mechanism targets active injury sites through chemotactic gradients. Without tissue damage creating those gradients, systemic TB-500 may not preferentially accumulate anywhere. If considering preventive use, limit duration to high-risk training blocks (4–8 weeks) rather than year-round administration, as long-term safety data for continuous use doesn't exist."}
{"question": "What is the difference between TB-500 and thymosin beta-4?", "answer": "TB-500 is a synthetic version of the active region of thymosin beta-4, specifically replicating the 7-amino acid sequence (Ac-SDKP) responsible for actin binding and cellular migration. Full-length thymosin beta-4 is a 43-amino acid peptide; TB-500 represents a shorter, more stable fragment retaining the therapeutic mechanism. Most research-grade TB-500 from reputable suppliers like Real Peptides contains this functional fragment at high purity, verified through third-party testing. The terms are often used interchangeably in peptide contexts, though technically TB-500 refers to the synthetic fragment specifically."}
{"question": "Should I inject TB-500 near the injury site or does injection location not matter?", "answer": "Injection location does not need to be near the injury site. TB-500 is administered subcutaneously (typically abdomen) and circulates systemically before accumulating at injury sites through chemotactic cellular signaling. Local injection near tendons or joints carries unnecessary risk of injection site complications without improving efficacy. The peptide finds injury sites through inflammatory markers and cellular damage signals, not through proximity to injection location."}
{"question": "Can TB-500 help with nerve damage or neuropathy?", "answer": "TB-500's mechanism focuses on promoting angiogenesis, cellular migration, and tissue remodeling. Processes relevant to muscle, tendon, and ligament repair but less directly applicable to nerve regeneration. Some animal studies suggest thymosin beta-4 may support neurite outgrowth and neural cell survival, but evidence for TB-500 effectiveness in peripheral neuropathy or nerve damage in humans is extremely limited. Conditions involving nerve compression secondary to inflammation (like carpal tunnel) might see indirect benefit from reduced swelling, but expecting meaningful nerve regeneration from TB-500 alone is not supported by current evidence."}
{"question": "How does TB-500 dosage for tissue repair compare to BPC-157 dosing?", "answer": "TB-500 and BPC-157 operate through distinct mechanisms at different dose ranges. TB-500 typically dosed at 2–10mg twice weekly, BPC-157 at 250–500mcg daily. TB-500 works through actin sequestration and angiogenesis; BPC-157 through growth factor upregulation (VEGF, EGF) and nitric oxide modulation. The peptides are often stacked because they target complementary pathways: TB-500 promotes cellular migration to injury sites, BPC-157 enhances vascular supply and extracellular matrix formation. Standard stacking protocol maintains full dosing of both rather than reducing either."}
{"question": "What happens if I miss a scheduled TB-500 injection during the loading phase?", "answer": "If you miss a dose during the loading phase, administer it as soon as you remember if fewer than three days have passed, then resume your regular schedule. If more than three days have passed, skip the missed dose and continue with your next scheduled injection. Do not double-dose to 'catch up' as this doesn't improve tissue saturation and may increase side effect risk. Missing 1–2 doses during a 4-week loading phase delays reaching tissue saturation by several days but doesn't negate prior progress."}
{"question": "Is TB-500 safe to use while recovering from surgery?", "answer": "TB-500 is generally considered safe for post-surgical use beginning 48–72 hours after surgery, allowing the initial inflammatory response to establish before peptide administration. The peptide's promotion of angiogenesis and cellular migration aligns with organized surgical wound healing phases. However, you must discuss peptide use with your surgeon before implementation. Some procedures involve specific healing timeline requirements where accelerated tissue remodeling could be counterproductive, and certain medications (anticoagulants, immunosuppressants) may interact with TB-500's effects on vascular development."}
{"question": "Does TB-500 require cycling or can it be used continuously?", "answer": "Most tissue repair protocols implement TB-500 for defined injury recovery periods (8–16 weeks) rather than indefinitely, both because injuries resolve and because long-term continuous use safety data doesn't exist in humans. After completing a 12-week protocol, most practitioners recommend at least 4–8 weeks off before starting another course if addressing a different injury. The peptide doesn't appear to produce tolerance or dependence, but continuous year-round administration is not standard practice and lacks supporting safety evidence."}
{"question": "Can TB-500 be used for chronic arthritis or joint degeneration?", "answer": "TB-500's mechanism targets soft tissue repair (muscle, tendon, ligament) through cellular migration and angiogenesis. It does not directly address cartilage regeneration or bone remodeling, the primary pathologies in osteoarthritis. Some users report reduced joint pain during TB-500 protocols, potentially from improved periarticular soft tissue condition and reduced inflammation, but this is not the peptide's primary indication. For joint cartilage repair, other compounds like BPC-157 or growth factors show more relevant mechanisms, though evidence remains limited across all peptide applications for cartilage damage."}
{"question": "What purity level should I look for when sourcing TB-500 for tissue repair research?", "answer": "Research-grade TB-500 should demonstrate ≥98% purity verified by third-party HPLC (high-performance liquid chromatography) testing, with complete amino acid sequencing confirmation. Lower purity products may contain synthesis byproducts, degradation fragments, or incorrect peptide sequences that reduce efficacy and increase contamination risk. Reputable suppliers provide batch-specific certificates of analysis. If COA documentation isn't readily available, the source is not research-grade. Every peptide in Real Peptides' catalog undergoes small-batch synthesis with exact amino-acid sequencing to guarantee lab reliability and purity."}
{"question": "Should TB-500 dosage be adjusted based on body weight?", "answer": "Standard TB-500 protocols for tissue repair use fixed doses (2–10mg) rather than body weight-adjusted dosing, partly because the mechanism targets localized tissue injury rather than systemic pharmacological effects where body weight typically matters. The doses derive from veterinary studies scaled to approximate human equivalents, then refined through clinical observation. A 60kg person and a 100kg person with similar Grade II hamstring tears would typically use the same 5–7.5mg twice-weekly loading protocol. The injury severity and tissue type determine dosing more than body mass."}
If those black pellets concern you, address storage and reconstitution precision before the first injection. Proper bacteriostatic water dilution and refrigerated storage at 2–8°C determine whether your stated dose achieves therapeutic tissue concentration or degrades into an expensive saline injection.
Most users report subjective improvement in pain and mobility within 7–14 days of starting a loading protocol at 5–10mg twice weekly, though this reflects early anti-inflammatory effects rather than completed tissue repair. Measurable structural healing — verified by imaging or functional testing — typically requires 4–8 weeks of consistent dosing, with chronic injuries requiring 8–12 weeks for meaningful collagen remodeling. The peptide’s mechanism (promoting cellular migration and angiogenesis) produces gradual cumulative benefit rather than immediate symptom resolution.
Preventive dosing at 2–2.5mg weekly is sometimes used by athletes during high-volume training periods, though evidence supporting this practice is limited to anecdotal reports. The peptide’s mechanism targets active injury sites through chemotactic gradients — without tissue damage creating those gradients, systemic TB-500 may not preferentially accumulate anywhere. If considering preventive use, limit duration to high-risk training blocks (4–8 weeks) rather than year-round administration, as long-term safety data for continuous use doesn’t exist.
TB-500 is a synthetic version of the active region of thymosin beta-4, specifically replicating the 7-amino acid sequence (Ac-SDKP) responsible for actin binding and cellular migration. Full-length thymosin beta-4 is a 43-amino acid peptide; TB-500 represents a shorter, more stable fragment retaining the therapeutic mechanism. Most research-grade TB-500 from reputable suppliers like Real Peptides contains this functional fragment at high purity, verified through third-party testing. The terms are often used interchangeably in peptide contexts, though technically TB-500 refers to the synthetic fragment specifically.
Injection location does not need to be near the injury site — TB-500 is administered subcutaneously (typically abdomen) and circulates systemically before accumulating at injury sites through chemotactic cellular signaling. Local injection near tendons or joints carries unnecessary risk of injection site complications without improving efficacy. The peptide finds injury sites through inflammatory markers and cellular damage signals, not through proximity to injection location.
TB-500’s mechanism focuses on promoting angiogenesis, cellular migration, and tissue remodeling — processes relevant to muscle, tendon, and ligament repair but less directly applicable to nerve regeneration. Some animal studies suggest thymosin beta-4 may support neurite outgrowth and neural cell survival, but evidence for TB-500 effectiveness in peripheral neuropathy or nerve damage in humans is extremely limited. Conditions involving nerve compression secondary to inflammation (like carpal tunnel) might see indirect benefit from reduced swelling, but expecting meaningful nerve regeneration from TB-500 alone is not supported by current evidence.
TB-500 and BPC-157 operate through distinct mechanisms at different dose ranges — TB-500 typically dosed at 2–10mg twice weekly, BPC-157 at 250–500mcg daily. TB-500 works through actin sequestration and angiogenesis; BPC-157 through growth factor upregulation (VEGF, EGF) and nitric oxide modulation. The peptides are often stacked because they target complementary pathways: TB-500 promotes cellular migration to injury sites, BPC-157 enhances vascular supply and extracellular matrix formation. Standard stacking protocol maintains full dosing of both rather than reducing either.
If you miss a dose during the loading phase, administer it as soon as you remember if fewer than three days have passed, then resume your regular schedule. If more than three days have passed, skip the missed dose and continue with your next scheduled injection — do not double-dose to ‘catch up’ as this doesn’t improve tissue saturation and may increase side effect risk. Missing 1–2 doses during a 4-week loading phase delays reaching tissue saturation by several days but doesn’t negate prior progress.
TB-500 is generally considered safe for post-surgical use beginning 48–72 hours after surgery, allowing the initial inflammatory response to establish before peptide administration. The peptide’s promotion of angiogenesis and cellular migration aligns with organized surgical wound healing phases. However, you must discuss peptide use with your surgeon before implementation — some procedures involve specific healing timeline requirements where accelerated tissue remodeling could be counterproductive, and certain medications (anticoagulants, immunosuppressants) may interact with TB-500’s effects on vascular development.
Most tissue repair protocols implement TB-500 for defined injury recovery periods (8–16 weeks) rather than indefinitely, both because injuries resolve and because long-term continuous use safety data doesn’t exist in humans. After completing a 12-week protocol, most practitioners recommend at least 4–8 weeks off before starting another course if addressing a different injury. The peptide doesn’t appear to produce tolerance or dependence, but continuous year-round administration is not standard practice and lacks supporting safety evidence.
TB-500’s mechanism targets soft tissue repair (muscle, tendon, ligament) through cellular migration and angiogenesis — it does not directly address cartilage regeneration or bone remodeling, the primary pathologies in osteoarthritis. Some users report reduced joint pain during TB-500 protocols, potentially from improved periarticular soft tissue condition and reduced inflammation, but this is not the peptide’s primary indication. For joint cartilage repair, other compounds like BPC-157 or growth factors show more relevant mechanisms, though evidence remains limited across all peptide applications for cartilage damage.
Research-grade TB-500 should demonstrate ≥98% purity verified by third-party HPLC (high-performance liquid chromatography) testing, with complete amino acid sequencing confirmation. Lower purity products may contain synthesis byproducts, degradation fragments, or incorrect peptide sequences that reduce efficacy and increase contamination risk. Reputable suppliers provide batch-specific certificates of analysis — if COA documentation isn’t readily available, the source is not research-grade. Every peptide in Real Peptides’ catalog undergoes small-batch synthesis with exact amino-acid sequencing to guarantee lab reliability and purity.
Standard TB-500 protocols for tissue repair use fixed doses (2–10mg) rather than body weight-adjusted dosing, partly because the mechanism targets localized tissue injury rather than systemic pharmacological effects where body weight typically matters. The doses derive from veterinary studies scaled to approximate human equivalents, then refined through clinical observation. A 60kg person and a 100kg person with similar Grade II hamstring tears would typically use the same 5–7.5mg twice-weekly loading protocol — the injury severity and tissue type determine dosing more than body mass.